Lumpectomy Yields Clinically ‘Acceptably Low’ Recurrence Rates in Breast Cancer Subtype

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota details the efficacy of breast-conserving surgery in patients with multiple ipsilateral breast cancer.

Patients with multiple ipsilateral breast cancer should now be able to consider breast conservation therapy as a suitable treatment option along with mastectomy following clinically acceptable local recurrence rate, according to Judy C. Boughey, MD.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about efficacy findings for breast conservation therapy in patients with multiple ipsilateral breast cancer from the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243).

According to Boughey’s presentation on the trial, 6 of 204 patients had developed local recurrence following surgery with an estimated cumulative incidence of local recurrence after 5 years of 3.1% (95% CI, 1.3%-6.4%). These data fulfilled the trial’s prespecified acceptable 5-year recurrence rate of less than 8%.

Transcript:

In this prospective clinical trial, we enrolled over 200 women with 2 or 3 foci of breast cancer. They were then treated with breast conserving surgery [with] lumpectomy, [thus] preserving the breast, followed [by] whole breast radiation therapy along with radiation to all of the lumpectomy sites.

In this trial, we set the boundary to be that the local recurrence rate could not be any higher than 8% with a 5-year follow-up. We [reported] the 5-year follow-up on the Alliance Z11102 clinical trial, which showed that in these patients who completed breast conserving therapy—so surgery and radiation therapy—the local recurrence rate at 5 years was 3.1%.

This is an acceptably low local recurrence rate, which is clinically acceptable. [Based on that], patients who have multiple ipsilateral breast cancer can now consider their treatment options to be either mastectomy or breast-conserving therapy.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Related Videos
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Related Content